Resource Center

May 16, 2022

The white paper published today shows that thermal ablation, a portable and effective tool for treating cervical precancer, has the potential to substantially expand access in low- and middle-income countries where almost 90 percent of deaths occur.

February 4, 2022

Cervical cancer is one of the most preventable types of cancer but continues to be a leading cause of disease and death for women in low- and middle-income countries (LMICs). More than 300,000 women die of cervical cancer each year, with more than 90 percent of deaths occurring in LMICs. Human papillomavirus (HPV) vaccination and...

January 13, 2022

Our monthly check-in with staff from around the world. Learn more about the people who work at CHAI.

December 13, 2021

As we revisit several of our most popular pieces of content from 2021, we focus not only on the challenges the pandemic has caused health programs across our partner countries, but also the resilience that our partners have shown in their response.

Cover of Market Report: Diabetes self-monitoring devices in LMICs - October 2021

October 5, 2021

The report is the first of its kind providing market intelligence on the current state of access to blood glucose self-monitoring devices in low- and middle-income countries.

October 4, 2021

CHAI's 2020 Annual Report is out now. The theme for the year is 'working with urgency'.

An African male healthcare worker checks the fluid levels in the patients IV drip

March 8, 2021

The expanded partnership will increase access to leading-edge cancer treatments in low- and middle-income countries including biologics and hormonal therapies.

Screening Trainings in Gwalior Medical College

February 4, 2021

In 2019, CHAI launched our cervical cancer program with support from Unitaid. We partnered with governments in seven low-and-middle income countries to scale up safe, effective, and affordable pre-cancer screening and treatment technologies and assist partner governments in achieving global cervical cancer elimination targets, aiming to reduce the rate of premature mortality from the disease by a third.